pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›CRD-1
drug · small molecule
save

CRD-1

Phase 3updated 3mo ago
by Merck KGaA🔗 ChEMBL
Phase 3
community read0 votes

🐶 often sniffed alongside

top 3
  • tagApproval4 co-mentions · 2 sources
  • drugCLADRIBINE2 co-mentions · 2 sources
  • tagSmall Molecule2 co-mentions · 2 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 14 investigational indications.

all catalysts(0)

nothing on the calendar yet

Trials studying CRD-1

  • phase4Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosiscompletedn=47
  • phase3Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)recruitingn=264
  • phase2Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasmsrecruitingn=62
  • phase2A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)recruitingn=86
  • phase2Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutationsrecruitingn=68
  • phase2Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AMLrecruitingn=20
  • phase2Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AMLrecruitingn=40
  • phase2BCL2i CLAG-M in R/R Acute Myeloid Leukemiarecruitingn=52
more trials →

News(0)

no news has mentioned this drug yet

trade names
Cladribine, Leustat, Leustatin, Litak, Mavenclad
generic
cladribine
indication
Myasthenia Gravis
phase
phase_3
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 23m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?